Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.42 -0.02 (-1.39%)
As of 07/24/2026 09:30 AM Eastern
Compare

HBP vs. PLI, ABCN, EMC, TH, and BCT

Should you buy Helix BioPharma stock or one of its competitors? MarketBeat compares Helix BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Helix BioPharma include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Theratechnologies (TH), and BriaCell Therapeutics (BCT). These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to ProMetic Life Sciences?

Helix BioPharma (TSE:HBP) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled ProMetic Life Sciences'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
ProMetic Life Sciences Neutral

Helix BioPharma has higher earnings, but lower revenue than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
ProMetic Life Sciences N/A N/A N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Helix BioPharma and ProMetic Life Sciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

Helix BioPharma (TSE:HBP) and VIVO Cannabis (CVE:ABCN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled VIVO Cannabis'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
VIVO Cannabis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
VIVO CannabisN/AN/AN/AN/AN/A

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
VIVO Cannabis N/A N/A N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Helix BioPharma and VIVO Cannabis tied by winning 2 of the 4 factors compared between the two stocks.

How does Helix BioPharma compare to Emblem?

Emblem (CVE:EMC) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Emblem's return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
EmblemN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Emblem has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71M43.02-$24.81M-$0.19N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Emblem's average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Emblem Neutral
Helix BioPharma Neutral

Summary

Emblem beats Helix BioPharma on 5 of the 8 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Theratechnologies (TSE:TH) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Theratechnologies has a beta of 0.256166, meaning that its share price is 74% less volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.431088, meaning that its share price is 57% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -11.81%. Theratechnologies' return on equity of 16.59% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Theratechnologies-11.81% 16.59% 5.15%
Helix BioPharma N/A -21.54%-279.98%

0.5% of Theratechnologies shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 1.2% of Theratechnologies shares are held by insiders. Comparatively, 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Theratechnologies' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Theratechnologies Neutral
Helix BioPharma Neutral

Summary

Theratechnologies beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

BriaCell Therapeutics (CVE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Neutral

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Summary

BriaCell Therapeutics and Helix BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$109.98MC$434.80MC$6.88BC$12.48B
Dividend Yield1.50%3.90%2.67%6.19%
P/E Ratio-35.503.1627.0036.95
Price / SalesN/A6,592.20492.309.44
Price / Cash11.3213.1350.5482.29
Price / Book7.3883.7010.284.39
Net Income-C$50.55M-C$96.07MC$3.60BC$299.09M
7 Day Performance1.43%-0.64%-1.29%0.61%
1 Month Performance2.90%-1.04%-0.38%1.06%
1 Year Performance33.96%56.21%18.32%30.89%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.42
-1.4%		N/A+35.2%C$109.98MN/AN/A9
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
EMC
Emblem
N/A$1.88
+1.6%		N/A+0.0%$245.45M$5.71MN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A+4.2%C$205.53MC$84.38MN/A103

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel